CPRX Catalyst Pharmaceuticals, Inc. Total Debt to Capital

Catalyst Pharmaceuticals minimizes risks by focusing on the therapy of rare muscle pathologies as a monopolist. External contractors' production capacities are operating seamlessly, and updated logistics guarantee precise delivery timelines. High barriers in the form of patents and strict FDA oversight protect the business. This chart of the asset's value with the 0.00 metric confirms the financial stability of Catalyst Pharmaceuticals (CPRX).

This indicator is calculated as the ratio of total liabilities to net equity, determining the business's degree of dependence on borrowed funds and its financial stability. For Catalyst Pharmaceuticals (CPRX), which controls an alternative-free therapy for rare diseases, the total debt-to-equity ratio demonstrates a balance between aggressive ecosystem development and the risk of liquidity loss.